- AGING CELL Journal
- June 2019
Digital Object Identifier (DOI)
International Standard Serial Number (ISSN)
- Vascular stiffness is a major cause of cardiovascular disease during normal aging and in Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder caused by ubiquitous progerin expression. This mutant form of lamin A causes premature aging associated with cardiovascular alterations that lead to death at an average age of 14.6 years. We investigated the mechanisms underlying vessel stiffness in Lmna(G609G/G609G) mice with ubiquitous progerin expression, and tested the effect of treatment with nitrites. We also bred Lmna(LCS/LCS)Tie2Cre(+/tg)and Lmna(LCS/LCS)SM22 alpha Cre(+/tg) mice, which express progerin specifically in endothelial cells (ECs) and in vascular smooth muscle cells (VSMCs), respectively, to determine the specific contribution of each cell type to vascular pathology. We found vessel stiffness and inward remodeling in arteries of Lmna(G609G/G609G) and Lmna(LCS/LCS)SM22 alpha Cre(+/tg), but not in those from Lmna(LCS/LCS)Tie2Cre(+/tg)mice. Structural alterations in aortas of progeroid mice were associated with decreased smooth muscle tissue content, increased collagen deposition, and decreased transverse waving of elastin layers in the media. Functional studies identified collagen (unlike elastin and the cytoskeleton) as an underlying cause of aortic stiffness in progeroid mice. Consistent with this, we found increased deposition of collagens III, IV, V, and XII in the media of progeroid aortas. Vessel stiffness and inward remodeling in progeroid mice were prevented by adding sodium nitrite in drinking water. In conclusion, Lmna(G609G/G609G) arteries exhibit stiffness and inward remodeling, mainly due to progerin-induced damage to VSMCs, which causes increased deposition of medial collagen and a secondary alteration in elastin structure. Treatment with nitrites prevents vascular stiffness in progeria.
- aging; dietary nitrite; progeria; smooth muscle cells; vascular stiffness; cardiovascular-disease enterprises; farnesylation inhibitors; major shareholders; clinical-trial; risk-factor; oxide; lonafarnib; children; roles; supplementation